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Summary We describe a case of mixed malaria infection in a returning traveller. We 
suggest that our patient had a chronic infection with Plasmodium vivax and that this 
reduced the severity of an acute infection with P. falciparum – an example of cross-
species immunity. 
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 1. Introduction 
Malaria is a common diagnosis in returning travellers;1 mixed malaria infections are 
seen less frequently. We report a case of a mixed malaria infection, and suggest that 
infection with one species may reduce the severity of the other infection. 
2. Case report 
A 25-year-old white man presented to the emergency clinic of the Hospital for 
Tropical Diseases, London, UK on 8 September 2008, shortly after returning from 
leading a 5 month expedition in Papua New Guinea. His symptoms began with a 
single episode of diarrhoea, which was followed by a 6 day history of dry cough, 
fever and sweats. While in Papua New Guinea he trekked in the jungle, and slept in 
hammocks under a mosquito net. He was not fully compliant with his malaria 
chemoprophylaxis, and took doxycycline only intermittently. Of note, before this 
expedition, he had lived in rural Tanzania for 2 years working on conservation 
projects, but was well during this period. 
On examination, he was pyrexial at 40.8 °C, but appeared well. Physical 
examination was unremarkable apart from pallor. Blood tests showed haemoglobin 
7.7 g and platelets 48 × 109/l; renal function was normal. A thin film demonstrated 
trophozoites and schizonts of Plasmodium falciparum, with 0.2% parasitaemia. In 
addition, all stages of P. vivax were seen (Figure 1). 
He was initially treated with oral quinine, 700 mg three times daily, followed by a stat 
dose of Fansidar (sulfadoxine–pyrimethamine; three 500 mg/25 mg tablets). His 
glucose-6-phosphate dehydrogenase levels were normal, and thus a 2 week course 
of primaquine 15 mg twice daily was prescribed. His parasitaemia cleared during his 
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admission, and by the fourth day only gametocytes of each species could be seen. 
On discharge, he was given a 1 month course of ferrous sulphate and folic acid in 
view of his anaemia. He made a full recovery. 
3. Discussion 
Immunity to malaria in humans is poorly understood, but is thought to be both 
species- and genotype- (within a species subclass) specific. It has been reported 
that in mixed infections in humans, cross-species or cross-genome interaction exists 
between malaria parasites.2 A reduction in the severity of malaria symptoms occurs 
in individuals pre-exposed to different species,3 and Plasmodium vivax infection may 
protect against the severe complications of P. falciparum.2,4 This effect is thought 
partially to explain the lower mortality rates from P. falciparum seen in the Asia–
Pacific region compared with Africa.5 A recent study has shown that sera from a 
volunteer experimentally infected with P. vivax suppressed the growth of P. 
falciparum in vitro.6 This effect was mediated via IgM antibodies, and could be the 
means by which P. vivax infection protects against P. falciparum.  
We propose that this case represents an example of cross-species protection. 
Patients with P. falciparum schizonts in their peripheral blood film are often 
extremely unwell, but this was not the case in our patient. In addition, his marked 
anaemia suggests that he had a chronic malaria infection, most likely with P. vivax, 
and an acute secondary infection, probably with P. falciparum, that precipitated the 
symptoms leading to admission. Although his intermittent chemoprophylaxis may 
have played a role, it is probable that a chronic dual infection was responsible for the 
suppression of the severe manifestations of disease in this case.  
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 [Figure legend]  
Figure 1 Giemsa-stained blood film showing an early trophozoite of Plasmodium 
falciparum (A) and a late trophozoite of P. vivax (B). 
